At Clinical High Risk for Psychosis: Outcome for Nonconverters by Addington, Jean et al.
At Clinical High Risk for Psychosis: Outcome for Nonconverters
Jean Addington, Ph.D., Barbara A. Cornblatt, Ph.D., Kristin S. Cadenhead, M.D., Tyrone D.
Cannon, Ph.D., Thomas H. McGlashan, M.D., Diana O. Perkins, M.D., Larry J. Seidman,
Ph.D., Ming T. Tsuang, M.D., Ph.D., Elaine F. Walker, Ph.D., Scott W. Woods, M.D., and
Robert Heinssen, Ph.D.
Department of Psychiatry, University of Calgary; the Department of Psychiatry, Zucker Hillside
Hospital, Long Island, N.Y.; the Department of Psychiatry, University of California San Diego, San
Diego; the Departments of Psychology and Psychiatry and Biobehavioral Sciences, University of
California Los Angeles, Los Angeles; the Department of Psychiatry, Yale University, New Haven,
Conn.; the Department of Psychiatry, University of North Carolina, Chapel Hill; the Department of
Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts
General Hospital, Boston; the Departments of Psychology and Psychiatry, Emory University,
Atlanta; the Schizophrenia Spectrum Research Program, Division of Adult Translational
Research, National Institute of Mental Health, Bethesda, Md
Abstract
Objective—A major focus of early intervention research is determining the risk of conversion to
psychosis and developing optimal algorithms of prediction. Although reported rates of
nonconversion vary in the literature, the nonconversion rate always encompasses a majority
(50%–85%) of the sample participants. Less is known about the outcome among this group,
referred to as false positive individuals.
Method—A longitudinal study was conducted of more than 300 prospectively identified
treatment-seeking individuals meeting criteria for a psychosis-risk syndrome. Participants were
recruited and evaluated across eight clinical research centers as part of the North American
Prodrome Longitudinal Study. Over a 2.5-year follow-up assessment period, 214 (71%)
participants had not made the transition to psychosis.
Results—The sample examined included 111 individuals who had at least 1 year of follow-up
data available and did not transition to psychosis within the study duration. In year 1, there was
significant improvement in ratings for attenuated positive and negative symptoms. However, at
least one attenuated positive symptom was still present for 43% of the sample at 1 year and for
41% at 2 years. At the follow-up timepoints, social and role functioning were significantly poorer
in the clinical sample relative to nonpsychiatric comparison subjects.
Conclusions—Help-seeking individuals who meet prodromal criteria appear to represent those
who are truly at risk for psychosis and are showing the first signs of illness, those who remit in
terms of the symptoms used to index clinical high-risk status, and those who continue to have
attenuated positive symptoms.
A major focus of schizophrenia research is early detection, particularly during the putative
prodromal phase of a psychotic disorder. One recent direction of this research is determining
the risk of conversion to full-blown psychosis and developing algorithms of prediction (1–3)
of this transition. Participants in such studies meet well-established prodromal criteria (4, 5)
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and are described as being at ultra high risk or clinical high risk of developing psychosis. In
the present study, the term clinical high risk is utilized. Studies typically follow participants
for 1 or 2 years. Although reported rates of conversion vary in the literature (1–3, 6, 7), a
majority of participants consistently do not develop psychosis during the course of a study.
The term false positive (6) has been used to describe such persons. Little, if any, data have
been reported about the outcome of these false positive individuals.
The North American Prodrome Longitudinal Study is a consortium of eight research centers
that ascertained clinical high-risk individuals and followed them for a period of up to 2½
years (1, 8). Although originally developed as independent studies, the investigations at the
eight sites employed similar ascertainment and diagnostic methods, making it possible to
form a standardized protocol for mapping data into a new scheme representing the common
components across sites (1, 8), yielding one of the largest databases of longitudinally
followed clinical high-risk cases worldwide. This data set includes 303 prospectively
identified treatment-seeking patients who met criteria for a psychosis-risk syndrome based
on the Structured Interview for Prodromal Syndromes (5, 9) and for whom follow-up data
were available. Of this sample, 71% had not made the transition to psychosis by the 2.5-year
follow-up assessment (1).
The goal of the present study was to determine the clinical and functional status of those
who did not convert to psychosis within the time frame of the study. The aims were to 1)
examine the change over time in attenuated positive symptoms, negative symptoms, and
functional outcome; 2) determine how many participants still met psychosis-risk syndrome
criteria at the follow-up time-points and how many still had attenuated positive symptoms;
and 3) determine whether those who did not convert to full-blown psychosis developed other
disorders. It was predicted that there would be an improvement in attenuated symptoms and
that there would be less improvement in functioning.
Method
Sample
Study protocols and informed consent documents, including procedures for data pooling and
secondary data analysis, were approved by the institutional review boards of the
participating sites (Emory University, Harvard University, University of California Los
Angeles, University of California San Diego, University of North Carolina, Universities of
Toronto and Calgary, Yale University, and Zucker Hillside Hospital). North American
Prodrome Longitudinal Study methods and complete details of the federated database have
been described elsewhere (1, 8, 10). Structured Interview for Prodromal Syndromes (5, 9)
criteria were used for study entry, and the Structured Clinical Interview for DSM-IV (SCID)
was used to assess general psychopathology.
Participants had to meet one of the three established criteria for a psychosis-risk syndrome
(11), which are as follows: attenuated psychotic symptom state, brief intermittent psychotic
state, and genetic risk with deterioration in functioning. Attenuated psychotic symptom state
emphasizes onset or worsening of attenuated positive symptoms in the past 12 months in at
least one of the following five symptom domains: unusual thought content, suspicion/
paranoia, grandiosity, perceptual anomalies, and disorganized communication. Participants
also qualified for a prodromal syndrome if they began displaying (in the past 3 months) brief
intermittent positive psychotic symptoms below the threshold required for a DSM-IV axis I
psychotic disorder diagnosis or if they possessed a genetic risk for psychosis and displayed
deterioration in functioning amounting to a 30% decline in their score on the Global
Assessment of Functioning (GAF) scale in the past 12 months. Genetic risk was defined as a
family history of psychosis in first-degree relatives or a diagnosis of schizotypal personality
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disorder. All North American Prodrome Longitudinal Study sites demonstrated good
reliability employing the prodromal criteria (kappa range: 0.80–1.00 across sites) (8, 9).
Criteria for participation in the present study were 1) meeting criteria for a psychosis-risk
syndrome, 2) having at least 1 year of follow-up assessment data available, and 3) having
not converted to psychosis. We excluded everyone who had ever received anti-psychotic
medication either prior to ascertainment or during the course of the study.
A total of 303 participants had at least one follow-up evaluation between the 6- and 42-
month duration of the North American Prodrome Longitudinal Study. Participants were
excluded from the present analyses if they converted to full-blown psychosis anytime after
baseline evaluation up until the 2.5-year follow-up assessment (N=89), did not have 1-year
follow-up evaluation data available (N=48), or had received antipsychotic medication at
some point during the study (N=55). Thus, our final nonconverting sample consisted of 111
individuals (men, N=62; women, N=49). The majority of these participants were Caucasian
(82%), with a mean age of 18 years (SD=4.9, range: 12–36). At ascertainment, 48.6% were
in high school, 20.7% were in college, 12.6% were unemployed, and 18% were working
full- or part-time. In our final sample, all participants met the criteria for the attenuated
positive symptom state. This is not unusual, since in clinical high-risk samples only a very
small proportion of individuals meet only criteria for a brief intermittent psychotic state or
genetic risk with deterioration in functioning (8). Of the 111 individuals in the present
sample, 76 had 2-year follow-up evaluation data available. Therefore, we know that 111 did
not convert to full-blown psychosis at 1 year, and nested within this group, 76 had not
converted by 2 years.
Fifty-five participants (men, N=35, women, N=20) who did not convert to full-blown
psychosis but had received treatment with an antipsychotic at some point during the follow-
up period were excluded. This group did not differ from the included sample with regard to
sex, age, and baseline positive attenuated or negative symptoms as assessed by the Scale of
Prodromal Symptoms (9). However, at baseline they had significantly lower scores on the
GAF scale (43.52 versus 51.89, t=4.59, p<0.0001) as well as significantly lower ratings on
global social (5.98 versus 6.65, t=2.73, p<0.01) and global role (5.91 versus 6.67, t=2.73,
p<0.01) functioning assessments compared with the present sample.
The North American Prodrome Longitudinal Study data set also followed a sample of
nonpsychiatric comparison subjects (N=139) (8). For the purpose of the present study, we
selected 111 who had received social and role functioning assessments and with whom we
matched on age and sex to our nonconverting sample.
Measures
Measures used to determine clinical status were the Scale of Prodromal Symptoms, for
attenuated positive and negative symptom ratings, and SCID, for axis I and II diagnoses. To
assess functioning, we used the GAF scale as well as the Global Functioning: Social and
Global Functioning: Role, two new measures of functioning. These measures of global
functioning were developed by Cornblatt et al. (12), specifically for the North American
Prodrome Longitudinal Study project to allow focus on functioning in the putatively
prodromal phase of illness (8, 12). These measures have excellent interrater reliability and
represent parallel well-anchored scales that account for age and phase of illness, distinguish
social from role functioning, and detect functional changes over time (12).
Analyses
1. Generalized linear mixed models were used to examine the change of symptoms
and functioning over 2 years. Independent t tests were used to compare ratings of
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the clinical high-risk group on the GAF scale and on the two measures of global
functioning at the follow-up timepoints with ratings of the nonpsychiatric
comparison group to determine whether the high-risk group continued to
demonstrate functional impairment.
2. To determine whether those participants who showed improvement in attenuated
symptoms had improved functioning and comorbidity, we divided them into two
groups based on whether they did or did not have any of the five positive symptoms
rated in the putatively prodromal range on the Scale of Prodromal Symptoms.
These two groups were compared on all functioning measures using t tests and on
the presence of an axis I diagnosis using chi-square tests.
3. We used Cochran’s Q test to determine whether there were changes in the
proportion of participants presenting with a DSM-IV diagnosis at the different
assessment times.
Results
Overall Changes in Symptoms and Functioning
Generalized linear mixed models for repeated-measures data were used to compare the least
squares means of positive symptoms, negative symptoms, social functioning, role
functioning, and GAF ratings for all participants at baseline, 1 year, and 2 years (Figure 1).
Means and standard deviations for these analyses are presented in Table 1. Although there
was an improvement over time in both positive and negative symptoms, the improvement
was only significant between baseline and 1 year (p<0.0001; p<0.001, respectively), not
from 1 year to 2 years. Ratings for social and role functioning improved at each assessment
period, but the improvement in both social and role functioning was only significant from
baseline to 1 year (p=0.002; p<0.0001, respectively). However, there was a significant
improvement in GAF scores between baseline and 1 year as well as between 1 year and 2
years (p<0.0001; p=0.04, respectively) (Table 1).
Using independent t tests, we compared our nonconverting sample with the nonpsychiatric
comparison group on social and role functioning. Even though we found improved
functioning among the nonconverting clinical high-risk participants at each assessment, this
group still performed more poorly on both social and role functioning relative to
nonpsychiatric comparison subjects. For social functioning, mean and t values at baseline
for the clinical high-risk group versus the comparison group were 6.65 (SD=1.51) versus
8.55 (SD=1.01), t=10.76; at 1 year the values were 7.15 (SD=1.43) versus 8.55 (SD=1.01),
t=8.25; and at 2 years the values were 7.30 (SD=1.54) versus 8.55 (SD=1.01), t=6.5 (all
values significant at p<0.0001). For role function, mean and t values at baseline for the
clinical high-risk group versus the comparison group were 6.67 (SD=1.76) versus 8.71
(SD=1.05), t=10.45 (p<0.0001); at 1 year the values were 7.35 (SD=1.30) versus 8.71
(SD=1.05), t=8.31 (p<0.01); and at 2 years the values were 7.30 (SD=1.46) versus 8.71
(SD=1.05), t=6.36 (p<0.01).
Prodromal Diagnostic Criteria
To meet attenuated positive symptom state, the attenuated positive symptoms must have
begun or worsened in the past 12 months. Thus, to meet prodromal criteria at the 1-year
follow-up assessment, there had to have been an increase in at least one attenuated positive
symptom by 1 point. At baseline, 100% of the present nonconverting sample met criteria for
attenuated positive symptom state, only six individuals (5.4%) met criteria at 1 year, and six
different individuals (5.4%) met criteria at 2 years. Thus, among the nonconverting sample
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there was a substantial decline in the number of those meeting actual prodromal criteria at
the follow-up assessments.
On the Scale of Prodromal Symptoms, a rating of 0–2 indicates that the symptom does not
meet criteria for being attenuated; a rating of 3–5 indicates that the symptom is attenuated
with different degrees of severity; and a rating of 6 indicates psychotic intensity. At the 1-
year follow-up assessment, 45 (42.9%) participants in the present clinical group had at least
one attenuated positive symptom (i.e., one of the five attenuated positive symptoms was
rated ≥3), and 31 (40.8%) had at least one attenuated positive symptom at 2 years. Those
who still had attenuated positive symptoms at 1 year versus those who did not showed no
difference in axis I or II diagnoses or social or role functioning at either baseline or the 1-
year follow-up assessment.
DSM Axis I and II Diagnoses
Both axis I and II diagnoses were examined. Axis I diagnoses were grouped into the
following clusters: any substance use disorder, anxiety disorder, mood disorder, and mania.
The percentages of participants that received these diagnoses at each timepoint are presented
in Table 2. One individual presented with mania at both the 12- and 24-month follow-up
timepoints, and another was diagnosed with mania only at the 12-month follow-up
assessment. We used Cochran’s Q test to determine whether the proportions of participants
with or without a given diagnosis were the same at the different assessment times. The
results demonstrated that there was a statistically significant difference in having anxiety
(p<0.0001) or depression (p<0.0001) overall and in having a substance use disorder overall
(p=0.02). Pairwise comparisons using a Bonferroni-corrected level of significance (p=0.017)
were performed to compare proportions at each timepoint (Table 2).
Only 71% of the present nonconverting sample (N=79) were assessed for axis II diagnoses.
Of this subsample of 79 individuals, 57% (N=45) had no diagnoses at any time, 29% (N=23)
had consistent diagnoses (i.e., the same diagnoses at baseline and follow-up assessment),
and 14% (N=11) had emerging diagnoses (i.e., met criteria for axis II diagnoses at a follow-
up assessment only). Some individuals had more than one diagnosis. Consistent diagnoses
were avoidant (N=5), borderline (N=4), schizotypy (N=3), paranoid (N=3), narcissistic
(N=1), and obsessive-compulsive (N=1) personality disorders. Emerging diagnoses were
avoidant (N=10), paranoid (N=4), borderline (N=3), and obsessive-compulsive (N=1)
personality disorders.
Comparison of Participants Who Did and Did Not Remit
There were no differences in age, gender, or social or role functioning between those whose
attenuated psychotic symptoms improved and those whose attenuated psychotic symptoms
remained. As would be expected, the one exception was that those who still had attenuated
positive symptoms had significantly higher ratings for attenuated positive symptoms at
baseline (t=2.6, p<0.01).
Discussion
This is one of the first studies to consider the outcome of individuals at clinical high risk of
developing psychosis who do not go on to develop a full-blown psychotic illness over a 2½-
year period. A recent, small Swiss study demonstrated evidence of transitory attenuated
positive symptoms in some individuals who did not convert (13). However, it was unclear
whether these young participants improved or whether the baseline presentation of the
nonconverting group was predictive of another disorder. Overall, in our study, the
nonconverting group demonstrated significant improvement in attenuated positive
Addington et al. Page 5













symptoms, negative symptoms, and social and role functioning. Although symptoms
declined significantly in this group overall, this was driven by a subgroup whose symptoms
improved over time. Furthermore, more than 50% of this nonconverting sample no longer
presented with any attenuated positive symptoms. However, despite a statistically significant
improvement in functioning, this group remained at a lower level of functioning than
nonpsychiatric comparison subjects. This suggests that initial prodromal categorization is
associated with persistent disability, at least for 2.5 years.
Axis I diagnoses tended to diminish in number over time rather than emerge, although a
relatively high proportion of clinical high-risk participants did have a mood and/or anxiety
disorder. Only a small proportion demonstrated an emerging axis II disorder.
Strengths of this data set are its large sample size and the well-defined criteria for a
psychosis-risk syndrome (8). There are also limitations to these data. First, the follow-up
evaluation was limited to 1 year and 2 years only. It is likely that a longer follow-up
assessment period may have identified additional conversions, particularly since the mean
age of this sample at the 1-year follow-up assessment was 19 years and the age of onset of a
first episode of psychosis is, on average, 20–24 years (14). Second, the data were originally
collected at independently functioning sites not following a common protocol. Third, the
outcome measures are constrained by what was common at all sites (8). Fourth, it is possible
that some individuals had episodes of transient psychotic-like experiences as reported in the
general population (15), but our clinical sample consisted of all help seekers and outcome is
mixed in terms of risk status among individuals who do not seek help and are identified in
population-based studies as having had psychotic-like experiences (16). Fifth, other
medications (e.g., antidepressants) may have had an effect on attenuated positive symptoms.
We did not assess this because details of medication status were not universally collected,
and for those who were receiving treatment with other medications, dosage and compliance
were unknown. However, a study of the entire North American Prodrome Longitudinal
Study sample demonstrated that with the same limitations, antidepressant use was not
significantly associated with a decline in attenuated positive symptoms (17). Finally, we
excluded those individuals who were receiving treatment with antipsychotics, and thus we
cannot say how they may have been distributed among the three groups (remission,
symptomatic, converted).
In summary, we found that help-seeking individuals who met attenuated positive symptom
risk criteria appeared to cluster into several groups over a 2.5-year period. Among the 255
participants with 1 year of follow-up data in the North American Prodrome Longitudinal
Study, approximately 35% developed a psychotic illness, 24% remitted their attenuated
symptoms, 20% retained attenuated positive symptoms at lower levels of severity than those
present at baseline, and 21% received an antipsychotic drug while in the prodromal phase
and therefore could not be used to represent the natural course. Thus, prodromal attenuated
positive symptoms may predict a more severe condition in some but by no means all cases.
Thus, better prediction requires a range of both clinical and biological marker-predictors in
the future
Overall, our results suggest that persons who meet symptom and functional criteria for a
psychosis-risk syndrome represent a collection of the following groups: 1) those who are
truly at risk for psychosis and are showing the first signs of disorder, 2) those who remit in
terms of the symptoms used to index clinical high-risk status, and 3) those who continue to
have attenuated positive symptoms. Future work is needed not only to replicate these
findings but to extend them over much longer follow-up periods and with more
comprehensive assessments that were beyond the scope of this project.
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Figure 1. Symptoms and Functioning Over Time in Patients at Clinical High Risk for Developing
Pyschosis, by Prodromal Symptom Statusa
a Patients were divided into groups according to whether they had a positive symptom rated
in the putatively prodromal range (P) or no prodromal positive symptoms (NP).
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